Evidence map›Paper›PMID 41957474›Full record

ArticleNPJ precision oncology2026

Terminal T-cell exhaustion predicts tumor control independent of immunotherapy in ovarian cancer.

Anna Salvioni, Marie Michelas, Mathilde Del, Pierre Vuattoux, Bertille Segier, Clara-Maria Scarlata, Noémie Thébault, Giulia C Leonardi, Nathalie Van Acker, François-Xavier Frenois and 17 more

Abstract read
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Anna SalvioniUniversité de Toulouse, CNRS, Inserm, Centre de recherches en cancérologie de Toulouse, Toulouse, France.
Marie Michelas *Université de Toulouse, CNRS, Inserm, Centre de recherches en cancérologie de Toulouse, Toulouse, France.
Mathilde Del *Université de Toulouse, CNRS, Inserm, Centre de recherches en cancérologie de Toulouse, Toulouse, France.
Pierre Vuattoux *Centre Hospitalier Universitaire (CHU), Institut universitaire du cancer de Toulouse - Oncopole, Toulouse, France.
Bertille Segier *Biostatistics & Health Data Science units, Institut universitaire du cancer de Toulouse - Oncopole, Toulouse, France.
Clara-Maria ScarlataUniversité de Toulouse, CNRS, Inserm, Centre de recherches en cancérologie de Toulouse, Toulouse, France.
Noémie ThébaultUniversité de Toulouse, CNRS, Inserm, Centre de recherches en cancérologie de Toulouse, Toulouse, France.
Giulia C LeonardiUniversité de Toulouse, CNRS, Inserm, Centre de recherches en cancérologie de Toulouse, Toulouse, France.
Nathalie Van AckerImag'IN Platform, Department of Pathology, Centre Hospitalier Universitaire (CHU), Institut universitaire du cancer de Toulouse - Oncopole, Toulouse, France.
François-Xavier FrenoisImag'IN Platform, Department of Pathology, Centre Hospitalier Universitaire (CHU), Institut universitaire du cancer de Toulouse - Oncopole, Toulouse, France.
Virginie FeliuUniversité de Toulouse, CNRS, Inserm, Centre de recherches en cancérologie de Toulouse, Toulouse, France.
Myriam MaixentUniversité de Toulouse, CNRS, Inserm, Centre de recherches en cancérologie de Toulouse, Toulouse, France.
Lise ScandellaUniversité de Toulouse, CNRS, Inserm, Centre de recherches en cancérologie de Toulouse, Toulouse, France.
Sylvie GiuriatoUniversité de Toulouse, CNRS, Inserm, Centre de recherches en cancérologie de Toulouse, Toulouse, France.
Claire IllacOncopole Claudius Regaud, Institut universitaire du cancer de Toulouse - Oncopole, Toulouse, France.
Sarah BetrianOncopole Claudius Regaud, Institut universitaire du cancer de Toulouse - Oncopole, Toulouse, France.
Charlotte CholletCentre Hospitalier Universitaire (CHU), Institut universitaire du cancer de Toulouse - Oncopole, Toulouse, France.
Bastien CabarrouBiostatistics & Health Data Science units, Institut universitaire du cancer de Toulouse - Oncopole, Toulouse, France.
Carlos Martinez-GomezUniversité de Toulouse, CNRS, Inserm, Centre de recherches en cancérologie de Toulouse, Toulouse, France.
Christel DevaudUniversité de Toulouse, CNRS, Inserm, Centre de recherches en cancérologie de Toulouse, Toulouse, France.
Ayman Al SaatiUniversité de Toulouse, CNRS, Inserm, Centre de recherches en cancérologie de Toulouse, Toulouse, France.
Christine ToulasUniversité de Toulouse, CNRS, Inserm, Centre de recherches en cancérologie de Toulouse, Toulouse, France.
Thomas FilleronBiostatistics & Health Data Science units, Institut universitaire du cancer de Toulouse - Oncopole, Toulouse, France.
Guillaume BataillonOncopole Claudius Regaud, Institut universitaire du cancer de Toulouse - Oncopole, Toulouse, France.
Jean-Pierre DelordUniversité de Toulouse, CNRS, Inserm, Centre de recherches en cancérologie de Toulouse, Toulouse, France.
Maha Ayyoub *Université de Toulouse, CNRS, Inserm, Centre de recherches en cancérologie de Toulouse, Toulouse, France. maha.ayyoub@inserm.fr.
Alejandra Martinez *Université de Toulouse, CNRS, Inserm, Centre de recherches en cancérologie de Toulouse, Toulouse, France. martinez.alejandra@iuct-oncopole.fr.

Funding

American Association for Cancer Research 22-40-12-SALV
6 · The paper itself

Abstract

T-cell exhaustion is typically studied in the context of immune checkpoint blockade, where proliferation and reinvigoration of exhausted cells drives therapeutic responses. However, terminal exhaustion may also represent a marker of chronic tumor-specific activation, raising the possibility that exhausted T cells reflect ongoing endogenous tumor control. Here, we sought to evaluate T-cell exhaustion as a prognostic marker using high-grade serous ovarian cancer (HGSC), an immunotherapy-resistant malignancy, as a model. In a cohort of 80 patients with stage III/IV HGSC, we assessed T-cell infiltration and exhaustion according to homologous recombination (HR) deficiency status. While overall immune infiltration was comparable between HR-deficient and proficient tumors, terminally exhausted CD8 and conventional CD4 T cells were enriched in HR-deficient tumors, where their presence correlated with improved progression-free survival. These findings suggest that exhausted T cells may indicate protective immunity even outside the context of immunotherapy and underscore their prognostic relevance in solid tumors.

Identifiers

PMID41957474
PMCPMC13250089

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.